Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Sebastian, Martin ^a   Papachristofilou, Alexandros ^b   Weiss, Christian ^a   Früh, Martin ^c   Cathomas, Richard ^d   Hilbe, Wolfgang ^e   Wehler, Thomas ^f   Rippin, Gerd ^g   Koch, Sven D ^h   Scheel, Birgit ^h   Fotin Mleczek, Mariola ^h   Heidenreich, Regina ^h   Kallen, Karl Josef ^h   Gnad Vogt, Ulrike ^h   Zippelius, Alfred ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Department of Radiation Therapy and Oncology Goethe University ^*  (Switzerland)

^d Medical Oncology   (Switzerland)

^e UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g Rippin Consulting   (Germany)

^h CureVac GmbH   (Germany)

Author keywords

CV9202; Local radiotherapy; mRNA vaccine; Non small cell lung cancer; RNActive

Indexed keywords

CANCER VACCINE; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MAINTENANCE THERAPY; NON SMALL CELL LUNG CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; ADJUVANT CHEMOTHERAPY; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; RADIOTHERAPY; TREATMENT OUTCOME;

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84908060936     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-748     Document Type: Article

References (61)

1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Database Available at: http://www.seer.cancer.gov; last accessed September 2013., National Cancer Institute.
2. Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:277S-289S. 10.1378/chest.07-1381, 17873174.
3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis MF, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551. 10.1200/JCO.2007.15.0375, 18506025.
4. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis MF, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531. 10.1016/S0140-6736(09)60569-9, 19410716.
5. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21:1804-1809. 10.1093/annonc/mdq020, 2924992, 20150572.
6. Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martinez-Barrera L, Barraclough H, van Kooten KM, Orlando M. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 2011, 6:1907-1914. 10.1097/JTO.0b013e318226b5fa, 22005471.
7. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388. 10.1056/NEJMoa0909530, 20573926.
8. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128. 10.1016/S1470-2045(09)70364-X, 20022809.
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, de Marinis MF, Corre R, Bover I, Illiano A, Dansin E, de Castro CJ, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246. 10.1016/S1470-2045(11)70393-X, 22285168.
10. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334. 10.1200/JCO.2012.44.2806, 23816960.
11. Wu YL, Zhou C, Hu CP, Feng JF, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Massey D, Shi Y, Chen J, Zazulina V, Geater SL. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. ASCO Meeting Abstracts 2013, 31:8016.
12. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas PT, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394. 10.1056/NEJMoa1214886, 23724913.
13. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina SE, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, As-Santagata D, Ladanyi M, Pao W. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 2012, 109:E2127-E2133. 10.1073/pnas.1203530109, 3411967, 22773810.
14. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012, 30:2046-2054. 10.1200/JCO.2011.38.4032, 22547592.
15. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465. 10.1056/NEJMoa1200694, 3563263, 22658128.
16. Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 2013, 20:22-31.
17. Neninger VE, de la Torre A, Osorio RM, Catala FM, Bravo I, del PM M, Abreu AD, Acosta BS, Rives R, del Castillo CC, Gonzalez DM, Viada C, Garcia VB, Crombet RT, Gonzalez MG, Lage DA. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:1452-1458. 10.1200/JCO.2007.11.5980, 18349395.
18. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005, 23:6674-6681. 10.1200/JCO.2005.13.011, 16170175.
19. Butts CA, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski MJ, Nawrocki S, Ciuleanu TE, Bosquee L, Trigo Perez JM, Spira AI, Tremblay L, Nyman J, Ramlau R, Helwig C, Falk MH, Shepherd FA. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 2013, 31:Abstract 7500.
20. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011, 12:1125-1133. 10.1016/S1470-2045(11)70259-5, 22019520.
21. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Vanakesa T, Jassem J, Kalofonos H, Perdeus J, Bonnet R, Basko J, Janilionis R, Passlick B, Treasure T, Gillet M, Lehmann FF, Brichard VG. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013, 31:2396-2403. 10.1200/JCO.2012.43.7103, 23715567.
22. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009, 10:371-374. 10.3816/CLC.2009.n.052, 19808198.
23. Sebastian M, Von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, Thomas M, Schneller F, Jan SW, Goekkurt E, Bernhard H, Groeschel A, Scheel B, Koch SD, Lander T, Rippin G, Wiegand V, Senta Gnad-Vogt U, Kallen KJ, Knuth A. Messenger RNA vaccination and B-cell responses in NSCLC patients. J Clin Oncol 2012, 30:Abstract 2573.
24. Giaccone G, Bazhenova L, Nemunaitis J, Juhasz E, Ramlau R, van den Heuvel MM, Lal R, Dunlop DJ, Carrier E, Fakhrai H. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC). European Cancer Congress 2013, Abstract LBA 2..
25. Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, Baumhof P, Scheel B, Koch SD, Fotin-Mleczek M. A novel, disruptive vaccination technology: Self-adjuvanted RNActive ((R)) vaccines. Hum Vaccin Immunother 2013, 9:2263-2276. 3906413, 23921513.
26. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S, Probst J, Kallen KJ. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011, 34:1-15. 10.1097/CJI.0b013e3181f7dbe8, 21150709.
27. Kubler H, Maurer T, Stenzl A, Feyerabend S, Steiner U, Schostak M, Schultze-Seemann W, Vom Dorp F, Pilla L, Viatali G, Hampel C, Wedel S, Trojan L, Hiller K, Sommerauer M, Jocham D, Scheel B, Lander T, Kallen K, Miller K. Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. J Clin Oncol 2011, Supp:Abstract 4535.
28. Krishnadas DK, Bai F, Lucas KG. Cancer testis antigen and immunotherapy. ImmunoTargets and Therapy 2013, 2013(2):11-19.
29. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 2000, 97:12198-12203. 10.1073/pnas.220413497, 17318, 11027314.
30. Kim SH, Lee S, Lee CH, Lee MK, Kim YD, Shin DH, Choi KU, Kim JY, Park DY, Sol MY. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung 2009, 187:401-411. 10.1007/s00408-009-9181-3, 19795170.
31. Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, DiJoseph JF, Karnoub M, Huang S, Diesl V, Behrens C, Choe SE, Rios C, Gruzas J, Sridharan L, Dougher M, Kunz A, Hamann PR, Evans D, Armellino D, Khandke K, Marquette K, Tchistiakova L, Boghaert ER, Abraham RT, Wistuba II, Zhou BB. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res 2011, 71:4236-4246. 10.1158/0008-5472.CAN-10-3919, 21540235.
32. Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One 2012, 7:e34100. 10.1371/journal.pone.0034100, 3311582, 22457815.
33. Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther 2007, 6:481-486. 10.4161/cbt.6.4.4201, 18027437.
34. Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, Tesniere A, Martins I, Ly A, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 2010, 22:113-124. 10.1016/j.smim.2010.03.001, 20403709.
35. Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012, 2:153. 3481113, 23112958.
36. Wersall PJ, Blomgren H, Pisa P, Lax I, Kalkner KM, Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 2006, 45:493-497. 10.1080/02841860600604611, 16760190.
37. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931. 10.1056/NEJMoa1112824, 3345206, 22397654.
38. Kroemer G, Zitvogel L. Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 2012, 1:407-408. 10.4161/onci.20074, 3382878, 22754758.
39. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059. 10.1038/nm1622, 17704786.
40. Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol 2012, 2:95. 3426850, 22937524.
41. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013, 105:256-265. 10.1093/jnci/djs629, 3576324, 23291374.
42. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, Van VP, Neefjes JJ. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006, 203:1259-1271. 10.1084/jem.20052494, 3212727, 16636135.
43. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004, 64:4328-4337. 10.1158/0008-5472.CAN-04-0073, 15205348.
44. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388. 10.1158/1078-0432.CCR-09-0265, 2746048, 19706802.
45. Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 2005, 11:4533-4544. 10.1158/1078-0432.CCR-04-2237, 15958639.
46. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012, 83:1306-1310. 10.1016/j.ijrobp.2011.09.049, 3337972, 22208977.
47. Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Kowalczyk A, Kallen KJ, Huber SM. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 2014, 9:180. doi:10.1186/1748-717X-9-180, 10.1186/1748-717X-9-180, 4150951, 25127546.
48. Budach W, Belka C. Palliative percutaneous radiotherapy in non-small-cell lung cancer. Lung Cancer 2004, 45(Suppl 2):S239-S245.
49. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lubbe AS, Reinhold T, Spath-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeboller H, Bocking A, Bohle RM, Bruske I, Burghuber O, Dickgreber N, Diederich S, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie 2011, 65:e51-e75. 10.1055/s-0030-1256562, 21830177.
50. McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S. A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A 2013, 83:728-738.
51. Janetzki S, Britten CM. The impact of harmonization on ELISPOT assay performance. Methods Mol Biol 2012, 792:25-36. 10.1007/978-1-61779-325-7_2, 21956498.
52. Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Lower M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010, 59:1489-1501. 10.1007/s00262-010-0875-4, 2909425, 20549207.
53. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008, 57:303-315. 10.1007/s00262-007-0380-6, 2150634, 17721781.
54. van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A. Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 2011, 3:108 ps44.
55. Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Welters MJ, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten CM. Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother 2013, 62:615-627. 10.1007/s00262-012-1359-5, 3624011, 23138872.
56. Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A. Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells. Cancer Immunol Immunother 2010, 59:609-618. 10.1007/s00262-009-0788-2, 2813531, 19894047.
57. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454. 10.1056/NEJMoa1200690, 3544539, 22658127.
58. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005, 11:3353-3362. 10.1158/1078-0432.CCR-04-2062, 15867235.
59. Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008, 14:5284-5291. 10.1158/1078-0432.CCR-07-5162, 2639763, 18698048.
60. John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P, Tsao MS, Deb S, Altorki N, Wright G, Knight S, Boutros PC, Cebon JS. The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS One 2013, 8:e67876. 10.1371/journal.pone.0067876, 3720740, 23935846.
61. Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, Chen YT, Old LJ. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 2000, 150:155-164. 10.1016/S0304-3835(99)00385-7, 10704737.